Clinical trial · Interventional
The Effect of Walking and Grounding in Women With Breast Cancer
The Effect of Walking and Grounding on Pain Intensity, Fatigue Level, and Sleep Quality in Women With Breast Cancer
NCT06767059CI-TRIAL-00113302completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This randomized controlled trial was conducted to examine the effect of walking and grounding on pain intensity, fatigue level and sleep quality in women diagnosed with breast cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Grounding Group | Other | — | UNRESOLVED |
| Walking Group | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- EXPERIMENTAL
- label
- Walking Group
- description
- Patients will walk for 30 minutes at least 3 times a week.
- interventionNames
- Other: Walking Group
- type
- EXPERIMENTAL
- label
- Grounding Group
- description
- Patients will walk with a grounding stick for 30 minutes at least 3 times a week.
- interventionNames
- Other: Grounding Group
- type
- NO_INTERVENTION
- label
- Control Group
- description
- Routine follow-up will be done.
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * 18 years of age or older, * Can read and write and speak Turkish, * Diagnosed with primary breast cancer and know the diagnosis, * Volunteered to participate in the research, * Living in Ankara province, * Paclitaxel or Paclitaxel-Transtuzumab based chemotherapy treatment initiated, * Eastern Cooperative Oncology Group (ECOG) Scale 0 or 1, * NCI-CTCAE v5.0 Pain, fatigue and sleep toxicity grade 1 or 2, * You have a phone with an iOS or Android processor, Exclusion Criteria: * Open wounds or edema of the hands and feet, * NCI-CTCAE v5.0 motor and sensory peripheral neuropathy with toxicity grade 3,4 or 5, * People with a disability that would prevent them from walking, * Diagnosed cardiovascular and pulmonary disorders, * Diagnosed neurological or psychiatric illness, * Communication problems, * Bone metastases, * Bilateral mastectomies, Criteria for Withdrawal from the Study: * Withdrawal from the study at any stage, * Hospitalization, * Failure to follow the guidelines or perform the intervention-walking for 30 minutes at least three times a week or walking plus grounding-in the intervention group, * Starting a regular exercise program during the study period in the control group.
References
Publications (0)
Data not yet available
No reference posted for this study.